Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Atara Biotherapeutics (ATRA) EBT (2022 - 2025)

Atara Biotherapeutics' EBT history spans 4 years, with the latest figure at -$3.4 million for Q4 2025.

  • For Q4 2025, EBT rose 72.99% year-over-year to -$3.4 million; the TTM value through Dec 2025 reached $32.7 million, up 138.35%, while the annual FY2025 figure was $32.7 million, 138.35% up from the prior year.
  • EBT reached -$3.4 million in Q4 2025 per ATRA's latest filing, up from -$4.3 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $38.0 million in Q1 2025 to a low of -$88.1 million in Q1 2022.
  • Average EBT over 4 years is -$34.8 million, with a median of -$26.8 million recorded in 2024.
  • Peak YoY movement for EBT: tumbled 485.07% in 2023, then skyrocketed 219.8% in 2025.
  • A 4-year view of EBT shows it stood at -$74.6 million in 2022, then grew by 18.62% to -$60.7 million in 2023, then skyrocketed by 79.22% to -$12.6 million in 2024, then surged by 72.99% to -$3.4 million in 2025.
  • Per Business Quant, the three most recent readings for ATRA's EBT are -$3.4 million (Q4 2025), -$4.3 million (Q3 2025), and $2.4 million (Q2 2025).